Latest Period
Q4 2025
Security Snapshot
Sarepta Therapeutics, Inc. - Common Stock (SRPT) Institutional Ownership
CUSIP: 803607100
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
342
Shares (Excl. Options)
93,379,419
Price
$21.52
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- SRPT on Nasdaq
- Shares outstanding
- 105,070,763
- Price per share
- $21.90
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 93,379,419
- Total reported value
- $2,009,412,127
- % of total 13F portfolios
- 0%
- Share change
- +7,671,068
- Value change
- +$171,274,911
- Number of holders
- 342
- Price from insider filings
- $21.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SRPT - Sarepta Therapeutics, Inc. - Common Stock is tracked under CUSIP 803607100.
- 342 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 342 to 178 between Q4 2025 and Q1 2026.
- Reported value moved from $2,009,412,127 to $697,230,468.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 342 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 803607100?
CUSIP 803607100 identifies SRPT - Sarepta Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 803607100:
Significant Owners of Sarepta Therapeutics, Inc. - Common Stock (SRPT) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13% | $284,766,671 | 13,232,652 | BlackRock, Inc. | 31 Dec 2025 | |||
| AQR CAPITAL MANAGEMENT LLC | 7.7% | $171,336,931 | 8,104,869 | AQR Capital Management, LLC | 31 Dec 2025 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.4% | $146,905,416 | 6,751,168 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1% | $116,831,964 | 5,369,116 | Vanguard Capital Management | 31 Mar 2026 | |||
| STATE STREET CORP | 5.4% | $102,225,558 | 5,304,907 | STATE STREET CORPORATION | 30 Sep 2025 | |||
| D. E. SHAW & CO, L.P. | 1.9% | -64% | $38,675,372 | -$58,829,132 | 2,007,025 | -60% | D. E. Shaw & Co., L.P. | 30 Sep 2025 |
| Capital International Investors | 0.5% | -98% | $9,523,733 | -$152,120,639 | 524,146 | -94% | Capital International Investors | 30 Jun 2025 |
As of 31 Dec 2025, 342 institutional investors reported holding 93,379,419 shares of Sarepta Therapeutics, Inc. - Common Stock (SRPT). This represents 89% of the company’s total 105,070,763 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Sarepta Therapeutics, Inc. - Common Stock (SRPT) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14% | 14,283,253 | +8.2% | 0.01% | $307,375,600 |
| VANGUARD GROUP INC | 11% | 11,810,729 | +9.2% | 0% | $254,166,887 |
| AQR CAPITAL MANAGEMENT LLC | 7.4% | 7,796,535 | +455% | 0.09% | $167,781,432 |
| STATE STREET CORP | 6.3% | 6,599,441 | +24% | 0% | $142,019,970 |
| Erste Asset Management GmbH | 2.6% | 2,728,945 | +1.6% | 0.49% | $58,726,896 |
| TWO SIGMA INVESTMENTS, LP | 2.3% | 2,441,455 | +14% | 0.08% | $52,540,112 |
| Aberdeen Group plc | 2.1% | 2,251,593 | +14% | 0.08% | $48,454,281 |
| TWO SIGMA ADVISERS, LP | 2% | 2,071,334 | +5.8% | 0.09% | $44,575,108 |
| UBS Group AG | 2% | 2,058,701 | +3.4% | 0.01% | $44,303,245 |
| FIRST TRUST ADVISORS LP | 1.9% | 1,992,577 | +2.7% | 0.03% | $42,880,264 |
| MORGAN STANLEY | 1.8% | 1,912,635 | -1.8% | 0% | $41,159,916 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,904,325 | +11% | 0% | $40,990,106 |
| BANK OF AMERICA CORP /DE/ | 1.6% | 1,694,590 | +111% | 0% | $36,467,583 |
| D. E. Shaw & Co., Inc. | 1.5% | 1,540,390 | -23% | 0.03% | $33,149,193 |
| FEDERATED HERMES, INC. | 1.2% | 1,313,313 | +0.35% | 0.05% | $28,262,496 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 1,159,578 | -56% | 0.04% | $24,954,119 |
| CITIGROUP INC | 1.1% | 1,146,175 | +12% | 0.02% | $24,665,686 |
| Connor, Clark & Lunn Investment Management Ltd. | 1% | 1,082,762 | -38% | 0.06% | $23,301,038 |
| MILLENNIUM MANAGEMENT LLC | 0.95% | 1,000,109 | +252% | 0.02% | $21,522,346 |
| T. Rowe Price Investment Management, Inc. | 0.85% | 892,065 | -35% | 0.01% | $19,198,000 |
| Voleon Capital Management LP | 0.84% | 879,953 | +76% | 0.41% | $18,936,589 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.84% | 878,393 | -33% | 0.07% | $18,903,017 |
| 683 Capital Management, LLC | 0.77% | 810,000 | -18% | 1.4% | $17,431,200 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.73% | 765,383 | +26% | 0% | $16,471,042 |
| JPMORGAN CHASE & CO | 0.71% | 743,988 | +11% | 0% | $16,010,622 |
Institutional Holders of Sarepta Therapeutics, Inc. - Common Stock (SRPT) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 32,202,465 | $697,230,468 | +$29,621,682 | $21.76 | 178 |
| 2025 Q4 | 93,379,419 | $2,009,412,127 | +$171,274,911 | $21.52 | 342 |
| 2025 Q3 | 86,798,814 | $1,674,545,829 | +$92,993,938 | $19.27 | 313 |
| 2025 Q2 | 82,768,888 | $1,414,059,003 | -$616,173,124 | $17.10 | 354 |
| 2025 Q1 | 85,664,154 | $5,483,381,207 | -$371,527,547 | $63.82 | 419 |
| 2024 Q4 | 87,843,903 | $10,682,091,570 | +$115,071,840 | $121.59 | 459 |
| 2024 Q3 | 86,796,388 | $10,834,992,283 | -$451,898,219 | $124.89 | 451 |
| 2024 Q2 | 88,782,224 | $14,026,709,174 | +$922,747,140 | $158.00 | 479 |
| 2024 Q1 | 83,236,471 | $10,771,794,424 | +$210,287,311 | $129.46 | 408 |
| 2023 Q4 | 81,574,475 | $7,866,654,991 | -$295,015,527 | $96.43 | 386 |
| 2023 Q3 | 83,265,476 | $10,092,124,857 | +$213,088,130 | $121.22 | 390 |
| 2023 Q2 | 81,723,093 | $9,359,752,457 | +$62,411,602 | $114.52 | 399 |
| 2023 Q1 | 81,211,200 | $11,191,507,838 | +$325,102,660 | $137.83 | 422 |
| 2022 Q4 | 78,931,000 | $10,227,280,074 | +$92,872,677 | $129.58 | 405 |
| 2022 Q3 | 78,254,620 | $8,650,122,111 | +$568,958,858 | $110.54 | 364 |
| 2022 Q2 | 73,313,897 | $5,496,320,989 | +$35,960,887 | $74.96 | 312 |
| 2022 Q1 | 73,015,967 | $5,705,221,328 | +$56,363,206 | $78.12 | 314 |
| 2021 Q4 | 71,894,248 | $6,474,592,585 | +$536,221,296 | $90.05 | 326 |
| 2021 Q3 | 65,753,485 | $6,079,879,477 | +$130,063,243 | $92.48 | 297 |
| 2021 Q2 | 64,801,548 | $5,037,256,042 | -$83,636,915 | $77.74 | 315 |
| 2021 Q1 | 66,263,834 | $4,936,320,529 | -$714,137,111 | $74.53 | 346 |
| 2020 Q4 | 70,628,202 | $12,036,993,873 | -$160,139,710 | $170.49 | 435 |
| 2020 Q3 | 72,104,327 | $10,123,672,605 | -$335,637,260 | $140.43 | 393 |
| 2020 Q2 | 73,863,151 | $11,844,121,308 | +$150,679,056 | $160.34 | 397 |
| 2020 Q1 | 73,412,115 | $7,179,418,082 | -$46,251,906 | $97.82 | 346 |
| 2019 Q4 | 73,511,794 | $9,484,309,752 | +$56,244,489 | $129.04 | 379 |
| 2019 Q3 | 73,245,840 | $5,516,516,594 | -$252,303,319 | $75.32 | 329 |
| 2019 Q2 | 71,710,913 | $10,889,813,246 | +$292,081,135 | $151.95 | 359 |
| 2019 Q1 | 71,059,216 | $8,477,596,090 | +$290,725,751 | $119.19 | 359 |
| 2018 Q4 | 68,661,818 | $7,492,575,765 | +$726,945,004 | $109.13 | 325 |
| 2018 Q3 | 61,212,693 | $9,884,755,828 | +$245,516,894 | $161.51 | 336 |
| 2018 Q2 | 59,953,943 | $7,924,528,334 | +$548,877,233 | $132.18 | 311 |
| 2018 Q1 | 56,761,587 | $4,203,831,314 | +$181,642,965 | $74.09 | 265 |
| 2017 Q4 | 55,206,092 | $3,072,290,058 | +$54,898,638 | $55.64 | 246 |
| 2017 Q3 | 53,730,465 | $2,441,631,878 | +$525,830,388 | $45.36 | 229 |
| 2017 Q2 | 42,713,217 | $1,439,533,207 | +$80,813,352 | $33.71 | 186 |
| 2017 Q1 | 40,738,464 | $1,205,704,254 | +$221,363,966 | $29.60 | 177 |
| 2016 Q4 | 39,367,759 | $1,079,914,087 | -$175,937,880 | $27.43 | 175 |
| 2016 Q3 | 42,406,897 | $2,603,203,193 | +$578,983,777 | $61.41 | 183 |
| 2016 Q2 | 34,630,592 | $660,414,393 | -$14,436,681 | $19.07 | 142 |
| 2016 Q1 | 35,134,647 | $685,755,808 | +$88,658,017 | $19.52 | 129 |
| 2015 Q4 | 28,532,796 | $1,100,883,608 | +$34,445,813 | $38.58 | 146 |
| 2015 Q3 | 27,764,899 | $891,509,724 | +$36,642,722 | $32.11 | 145 |
| 2015 Q2 | 26,667,019 | $811,458,439 | +$87,268,791 | $30.43 | 127 |
| 2015 Q1 | 24,203,223 | $321,208,632 | -$7,502,400 | $13.28 | 111 |
| 2014 Q4 | 24,718,769 | $357,295,111 | -$43,901,247 | $14.47 | 118 |
| 2014 Q3 | 25,967,938 | $547,925,873 | -$18,480,997 | $21.10 | 121 |
| 2014 Q2 | 26,655,127 | $794,069,375 | +$1,202,234 | $29.79 | 126 |
| 2014 Q1 | 26,596,410 | $639,243,096 | -$12,446,044 | $24.03 | 114 |